Diabetes and obesity care are two engines fueling the pharmaceutical industry right now. Novo Nordisk (NYSE: NVO) is at the forefront of these markets thanks to its red-hot blockbuster drugs Ozempic, Rybelsus, and Wegovy.

2024 has been a milestone year for Novo Nordisk, and the momentum doesn't appear to be slowing down. Let's dig into the company's latest wins and assess if now is a good time to scoop up some shares.

Oftentimes, pharmaceutical companies will seek alternative uses for their most successful medications. These are known as expanded indications; they go through a separate and robust clinical-trial process with the Food and Drug Administration (FDA).

Continue reading

Source Fool.com